 "Cipla launches diagnostic device, says it will provide results in minutes")
Drugmaker Cipla said on Wednesday it has launched a diagnostic device to test for diabetes, infectious diseases, cardiac markers, thyroid function and other conditions.
Cippoint will allow healthcare professionals to get test results in 3 to 15 minutes, enabling a faster clinical decision-making process. The device has an automated system and is user-friendly and it can be used in remote areas or mobile vans, said the company.
Cipla did not disclose the device’s price and where it will be deployed: at doctors' clinics or for home-use by consumers.
Cippoint offers a wide range of parameters to test for cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers, said the Mumbai-based company in a statement.
The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions, it added.
"We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum," said Achin Gupta, chief executive officer or Cipla One India Business.
Cipla, in FY 2021-22, launched a range of Covid-19 related diagnostic tests (antibodies and rapid antigen).
Cippoint will allow healthcare professionals to get test results in 3 to 15 minutes, enabling a faster clinical decision-making process. The device has an automated system and is user-friendly and it can be used in remote areas or mobile vans, said the company.
Cipla did not disclose the device’s price and where it will be deployed: at doctors' clinics or for home-use by consumers.
Also Read
The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions, it added.
"We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum," said Achin Gupta, chief executive officer or Cipla One India Business.
Cipla, in FY 2021-22, launched a range of Covid-19 related diagnostic tests (antibodies and rapid antigen).
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →Subscribe to Business Standard digital and get complimentary access to The New York Times
Quarterly Starter
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
Save 46%
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%